October 2016 Blog Posts (23)


Staff
Catabasis Completes Target Enrollment for Part B of the MoveDMD® Trial, a Phase 2 Trial of Edasalonexent (CAT-1004) for the Potential Treatment of Duchenne Muscular Dystrophy

Catabasis announced that target enrollment of 30 patients has been reached for Part B of the MoveDMD trial, a 12-week trial to assess the safety and efficacy of edasalonexent (CAT-1004) in Duchenne. Edasalonexent is an oral small molecule that the company believes has the potential to be a…

Continue

Added by PPMD on October 4, 2016 at 11:00am — No Comments


Staff
New Research Validates Translarna's™ (ataluren) Mechanism of Action to Promote Readthrough of Nonsense Mutations and Produce Full-length Functional Protein

PTC Therapeutics announced that the Proceedings of the National Academy of Sciences (PNAS) has published new results further validating Translarna's™ (ataluren) mechanism of action to promote readthrough of premature stop codons resulting from nonsense mutations in…

Continue

Added by PPMD on October 4, 2016 at 11:00am — No Comments


Staff
Sarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy

Today, Sarepta Therapeutics and Summit announced a license and collaboration agreement, which grants Sarepta the right to commercialize Summit's utrophin modulators in Europe should they receive approval. This includes ezutromid, which is currently in the Phase 2 PhaseOut DMD trial. PPMD will be hosting a community update call with…

Continue

Added by PPMD on October 4, 2016 at 8:30am — No Comments

Monthly Archives

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

Need help using this community site? Visit Ning's Help Page.

Members

Events

© 2019   Created by PPMD.   Powered by

Badges  |  Report an Issue  |  Privacy Policy  |  Terms of Service